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Results:	 The	 cumulative	 incidence	 was	 1.8%	 for	 sepsis	 and	 0.5%	 for	 severe	 sepsis.	
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1  | INTRODUCTION
Every	 day,	 approximately	 830	women	 die	worldwide	 as	 a	 result	 of	
pregnancy	and	childbirth.1	Most	maternal	deaths	(99%)	occur	in	low-	
and	middle-	income	countries	(LMICs),1	and	are	caused	by	hemorrhage	
(27%),	 hypertensive	 disorders	 (14%),	 or	 sepsis	 (10.7%).2	 Classifying	
death	 by	 a	 single	 primary	 cause,	 however,	 misses	 the	 potentially	
important	contribution	of	other	morbidities	and	their	interactions.
Imprecise	 and	 varying	 definitions	 of	 maternal	 sepsis	 have	 been	
used	for	many	years.	In	2017,	WHO	responded	by	proposing	a	defi-
nition	of	maternal	 sepsis	 as	 a	 “life-	threatening	 condition	defined	 as	





nal	 conditions	 (obesity,	 diabetes,	 malnutrition,	 severe	 anemia)	 and	
factors	related	to	childbirth	 (cesarean	delivery,	prolonged	rupture	of	
membranes,	 multiple	 vaginal	 examinations,	 placental	 retention).5–7 
Interest	in	postpartum	hemorrhage	(PPH)	as	a	risk	factor	for	sepsis	has	
recently	 been	 sparked	 by	 an	 association	 found	 in	 population-	based	
studies	in	high-	income	countries.8–11	It	is	possible	that	invasive	treat-
ments	 for	 PPH,	 such	 as	 intrauterine	 tamponade	 and	 hysterectomy,	
could	 increase	 the	 risk	of	 infection	by	 introducing	 (vaginal)	 bacteria	
into	the	uterus	and	abdomen.
Despite	 the	 possible	 infectious	 risk,	 antibiotic	 prophylaxis	 is	
rarely	and	inconsistently	mentioned	in	PPH	treatment	guidelines;	the	
American	College	of	Obstetricians	and	Gynecologists	12	and	the	Royal	
College	 of	Obstetricians	 and	Gynaecologists	 in	 the	 UK	 13	 make	 no	
mention	 at	 all.	WHO	guidelines	 only	 recommend	prophylactic	 anti-
biotics	for	manual	removal	of	the	placenta.14	This	difference	in	guide-
lines	indicates	a	lack	of	evidence	in	the	area.
The	 World	 Maternal	 Antifibrinolytic	 (WOMAN)	 trial	 recruited	





2  | MATERIALS AND METHODS






or	 a	 combination	of	 the	 uterine	 artery,	 ovarian	 artery,	 internal	 iliac	
artery),	intrauterine	tamponade,	and	“laparotomy	for	other	reasons.”
The	 WOMAN	 trial	 is	 a	 randomized,	 double-	blind,	 placebo-	
controlled	trial	to	evaluate	the	effect	of	tranexamic	acid	on	mortality	







primary	 cause	 of	 bleeding,	 and	 use	 of	 uterotonics.	 Hemodynamic	
instability	at	entry	was	based	on	clinical	signs	(e.g.	low	blood	pressure,	









inflammatory	 response,	 in	 line	with	 the	 previous	 adult	 definition	 of	










atinine	 rise	of	200%	or	more	 from	 index	 serum	creatinine	or	 serum	
creatinine	increased	to	350	μmol/L	(4	mg/dL).	Cardiac	failure	required	
the	 presence	 of	 typical	 signs	 or	 symptoms	 (e.g.	 orthopnea,	 hepato-
jugular	reflux)	or	a	reduced	left	ventricular	ejection	fraction,	relevant	
structural	 heart	 disease,	 or	 diastolic	 dysfunction.	 Respiratory	 failure	
required	 a	partial	 pressure	of	oxygen	 less	 than	60	mm	Hg	 (8.0	 kPa)	
on	 room	air,	 sea	 level.	Hepatic	 failure	 required	deterioration	 in	 liver	
function	with	 changes	 in	mental	 status	 and	 coagulopathy.	No	other	
types	of	organ	dysfunction	were	recorded	(Table	S1	holds	“guidance	
on	diagnosing	complications”).
Percentages	 and	medians	were	 used	 to	 describe	 the	 data.	 Risk	












Comprehensive	 logistic	 regression	 models	 with	 random	 effects	
were	 also	 used	 to	 assess	 the	 effect	 of	 (severe)	 sepsis	 on	 all-	cause	
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of	 the	 London	 School	 of	 Hygiene	 and	 Tropical	 Medicine	 (LSTHM).	
Ethical	approval	for	secondary	data	analysis	was	granted	by	the	eth-





A	total	of	20	060	women	with	PPH	were	 included	 in	 the	WOMAN	
trial,	with	a	mean	age	of	28	years.	Data	on	sepsis	were	available	for	



















intrauterine	 tamponade	 (aOR	 1.77;	 95%	 CI,	 1.21–2.59])	 remained	
essentially	unchanged	(P=0.004).
The	model	for	severe	sepsis	adjusted	for	the	same	confounders	as	
above,	 including	bleeding	severity,	but	contained	 fewer	events	 (104	
cases	 of	 severe	 sepsis).	The	 confidence	 intervals	 are	wider,	 but	 the	
main	 results	 remain	 similar.	 The	 risk	 factors	 associated	with	 severe	
sepsis	were	hysterectomy	(aOR	1.97;	0.83–2.46;	P=0.033),	intrauter-
ine	tamponade	(aOR	2.60;	95%	CI,	1.47–4.59;	P=0.002),	laparotomy	
(aOR	 5.35;	 95%	CI,	 2.61–10.98;	P<0.001),	 and	 artery	 ligation	 (aOR	
2.50;	1.28–4.89;	P=0.010)	(Table	2).







times	 (aOR	19.52;	95%	11.27–33.81)	 (Table	3).	Mortality	 in	women	








differences	 in	 methods	 and	 definitions.	 However,	 the	 incidence	 of	
1.8%	 in	our	study	seems	high	compared	with	previous	figures.6,17,18 
This	 supports	 the	 hypothesis	 of	 an	 increased	 sepsis	 risk	 in	women	































been	 raised	 since	 the	 1950s,	 but	 the	 currently	 used	 balloon	 tam-
ponades	 are	 deemed	 safer	 in	 general	 than	 gauze	packing.	All	major	
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TABLE  1 Characteristics	of	the	study	population	and	univariate	analysis	of	risk	factors	for	sepsis	and	severe	sepsis	(n=20	018).
Characteristics No. of women Cases of sepsis (%) Crude OR (95% CI)a Cases of severe sepsis (%) Crude OR (95% CI)a
Type	of	delivery
Vaginal 14 189 193	(1.36) 1 63	(0.44) 1
Cesarean 5824 170	(2.91) 2.51	(2.00–3.16) 41	(0.70) 1.80	(1.17–2.77)
Missing 5 2 0
Age	group,	y
≤20 1978 31	(1.56) 1.10	(0.71–1.70) 8	(0.40) 1.47	(0.62–3.50)
20–25 4864 78	(1.60) 1 17	(0.35) 1
>25–30 6794 109	(1.60) 1.03	(0.76–1.39) 33	(0.49) 1.60	(0.88–2.94)
>30–40 6066 140	(2.30) 1.38	(1.03–1.85) 43	(0.71) 2.34	(1.30–4.22)
>40 309 7	(2.25) 1.52	(0.67–3.44) 3	(0.97) 3.32	(0.91–12.13
Missing 7 0 0
Hospital	delivery
Yes 17	587 294	(1.67) 1 82	(0.47) 1
No 2428 70	(2.88) 1.43	(1.07–1.92) 22	(0.91) 1.69	(1.02–2.86)
Unknown 3 1 0
Primary	cause	of	hemorrhage
Atony 12	759 165	(1.29) 1 50	(0.39) 1
Trauma 3681 88	(2.38) 1.60	(1.21–2.10) 22	(0.60) 1.17	(0.69–1.98)
Placenta	previa/accreta 1874 57	(3.04) 1.60	(1.15–2.22) 11	(0.59) 0.78	(0.39–1.56)
Other 1454 45	(3.09) 1.69	(1.19–2.41) 19	(1.31) 2.17	(1.23–3.88)
Unknown 250 10 2
Prophylactic	uterotonics
Yes 19	265 341	(1.77) 1 94	(0.49) 1
No 269 14	(5.19) 2.25	(1.25–4.06) 6	(2.23) 3.84	(1.56–9.42)
Unknown 484 10 4
Hemodynamic	instability
No 8194 66	(0.80) 1 12	(0.15) 1
Yes 11 823 299	(2.52) 3.17	(2.37–4.24) 92	(0.78) 6.39	(3.36–12.13)
Unknown 1 0 0
Estimated	blood	loss,	mL
≤1000 10 402 93	(0.89) 1 28	(0.27) 1
1001–2000 8284 206	(2.48) 3.01	(2.29–3.95) 50	(0.60) 3.20	(1.87–5.48)
>2000 1330 66	(4.94) 5.75	(4.02–8.21) 26	(1.95) 10.21	(5.39–19.35)
Unknown 2 0 0
Systolic	blood	pressure,	mm	Hg
≥100 12 097 156	(1.29) 1 31	(0.26) 1
90–99 4081 65	(1.59) 1.24	(0.92–1.70) 21	(0.51) 1.93	(1.08–3.45)
<90 3835 144	(3.74) 3.07	(2.39–3.94) 52	(1.36) 6.03	(3.72–9.79)
Unknown 5 0 0
Hysterectomy
No 18 997 293	(1.54) 1 79	(0.42) 1
Yes 1020 72	(7.06) 4.55	(3.41–6.07) 25	(2.45) 5.87	(3.56–9.66)
Unknown 1 0 0
(Continues)





settings.23	 However,	 from	 the	 13	 reviewed	 studies,	 six	 were	 case	
series	or	case	reports	and	none	had	a	comparison	group.	Uterotonics	












Of	course,	a	 lifesaving	 intervention	should	never	be	withheld	 to	





All	 recent	 publications	 that	 showed	 an	 association	 between	 sepsis	
and	PPH	were	from	studies	in	high-	income	countries	with	low	levels	
of	maternal	mortality	 8–11	 or	 only	 included	women	who	had	under-
gone	cesarean	delivery.19	The	WOMAN	 trial	 is	 a	 large	multicountry	
study	predominantly	 in	LMICs.	Recorded	variables	were	well-	chosen	
for	low-	resource	settings	and	data	collection	was	nearly	complete	for	












admissions	 following	 surgical	 interventions	 for	 PPH	 provide	 more	
opportunity	for	sepsis	to	be	diagnosed,	and	the	effect	is	thus	potentially	
Characteristics No. of women Cases of sepsis (%) Crude OR (95% CI)a Cases of severe sepsis (%) Crude OR (95% CI)a
Manual	placenta	removal
No 18 138 302	(1.67) 1 89	(0.49) 1
Yes 1879 63	(3.35) 1.42	(1.05–1.93) 15	(0.80) 1.18	(0.66–2.12)
Unknown 1 1 0
Intrauterine	tamponade
No 18	583 310	(1.67) 1 73	(0.39) 1
Yes 1434 55	(3.84) 1.97	(1.38–2.82) 31	(2.13) 2.955	(1.74–5.02)
Unknown 1 1 0
Embolization
No 19 994 363	(1.82) 1 102	(0.51) 1
Yes 23 2	(8.7) 6.39	(1.23–33.35) 2	(8.7) 40.70	(7.00–236.52)
Unknown 1 1 0
Laparotomy
No 19 808 323	(1.63) 1 88	(0.44) 1
Yes 209 42	(20.1) 13.38	(8.98–19.93) 16	(7.66) 16.22	(8.66–30.32)
Unknown 1 1 0
Brace	sutures
No 19 467 339	(1.74) 1 91	(0.47) 1
Yes 550 26	(4.73) 2.67	(1.72–4.16) 13	(2.36) 4.35	(2.27–8.31)
Unknown 1 1 0
Artery	ligation
No 19	538 328	(1.68) 1 83	(0.42) 1
Yes 479 37	(7.72) 3.91	(2.63–5.82) 21	(4.38) 6.76	(3.85–11.87)
Unknown 1 1 0
aLogistic	regression	with	random	effects	to	account	for	clustering.
TABLE  1  (Continued)	







time	 (outcome	 form).	 Reversed	 causation	 is	 therefore	 a	 real	 danger.	
Sepsis	can	indeed	cause	bleeding,	through	a	cascade	of	organ	dysfunc-





aORa CI P valueb aORa CI P valueb
Hysterectomy 1.97 1.49–2.65 <0.001 1.97 0.83–2.46 0.033
Manual	placenta	removal 1.30 0.92–1.83 0.139 0.90 0.46–1.74 0.750
Intrauterine	tamponade 1.77 1.21–2.59 0.004 2.60 1.47–4.59 0.002
Laparotomy 6.63 4.29–10.24 <0.001 5.35 2.61–10.98 <0.001
Brace	sutures 1.09 0.66–1.81 0.7369 1.36 0.62–2.99 0.454
Artery	ligation 1.48 0.94–2.34 0.098 2.50 1.28–4.89 0.010
Age,	y 0.891 0.652
20–25	y 1 1
25–30	y 0.93 0.67–1.27 1.36 0.72–2.56
30–40 y 1.02 0.75–1.39 1.63 0.87–3.07
>40 0.76 0.30–1.91 1.37 0.32–5.79
≤20 1.09 0.69–1.73 1.40 0.56–3.46
Cesarean	delivery 1.99 1.49–2.65 <0.001 1.43 0.83–2.46 0.197
Estimated	blood	loss,	mL 0.006 0.139
≤1000 1 1
1001–2000 1.65 1.21–2.26 1.66 0.89–3.10
>2000 1.53 0.99–2.40 2.17 0.99–4.78
Systolic	blood	pressure,	mm	Hg <0.001 0.003
≥100 1 1
90–99 0.85 0.61–1.18 1.05 0.58–1.98
<90 1.57 1.17–2.13 2.36 1.32–4.19
Primary	cause	of	hemorrhage 0.016 0.002
Atony 1 1
Trauma 1.40 1.05–1.88 0.93 0.52–1.66
Placenta	previa/accreta 0.91 0.63–1.32 0.47 0.22–1.02
Other 1.54 1.06–2.23 2.37 1.31–4.29
Nonhospital	delivery 1.34 0.96–1.88 0.088 1.12 0.62–2.03 0.713
Signs	of	hemodynamic	
instability





Deaths/no. (%) Odds ratio 95% CI P value
No	sepsis 428/19	653	(2.8) 1
Any	type	of	sepsis 55/365	(15.1) 3.90 2.68–5.66 <0.001
Nonsevere	sepsis 13/261	(5.0) 0.99 0.51–1.89
Severe	sepsis 42/104	(40.4) 19.52 11.27–33.81 <0.001
aAdjusted	for	age,	type	of	delivery,	signs	of	hemodynamic	instability,	hospital	delivery,	primary	cause	of	hemorrhage,	laparotomy,	intrauterine	tamponade,	
artery	ligation,	hysterectomy,	brace	sutures,	and	clustering.
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than	causing	 it.	 Indeed,	 for	11%	of	hysterectomies	 the	stated	 reason	







In	 conclusion,	 PPH	 and	 postpartum	 sepsis	 remain	 important	




to	 investigate	 this	 finding	 further	 and	 examine	ways	 to	 reduce	 the	
risk,	including	clearer	guidelines	on	the	use	of	prophylactic	antibiotics.	
In	 the	 interim,	 potential	 harms	 and	benefits	 of	 these	 interventions,	
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